1,2,3,5-tetrahydrospiro[4H-1-benzazepine-4,3'-pyrrolidin]-2'-one | 1014991-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1,2,3,5-tetrahydrospiro[4H-1-benzazepine-4,3'-pyrrolidin]-2'-one
• 英文别名: Spiro[1,2,3,5-tetrahydro-1-benzazepine-4,3'-pyrrolidine]-2'-one
• CAS: 1014991-01-5
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: KGLYGUBREDCLLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• SUBSTITUTED SPIROHETEROCYCLES
  申请人：Xiang A. Min

  公开号：US20080076754A1

  公开（公告）日：2008-03-27

  The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

  本发明涉及公式I的非肽取代的螺环异杂苯并环己烯，其可用作血管加压素受体拮抗剂，用于治疗与血管加压素受体活性有关的情况，如涉及增加血管阻力和心脏不全的情况，包括充血性心力衰竭、低钠血症和高血压等。还公开了包含公式I化合物的药物组合物和治疗高血压、充血性心力衰竭、心脏不全、冠状动脉痉挛、心肌缺血、肝硬化、低钠血症、肾脏痉挛、肾衰竭、糖尿病肾病、脑水肿、脑缺血、中风、血栓形成或水肿等情况的方法。
• US7825111B2
  申请人：——

  公开号：US7825111B2

  公开（公告）日：2010-11-02